文献速递慢性静脉疾病

扩展中心静脉恢复研究:Medicare与非Medicare资格患者慢性静脉功能不全治疗结果的比较

Extended Center for Vein Restoration study assessing comparative outcomes for the treatment of chronic venous insufficiency in Medicare- and non-Medicare-eligible patients.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-05-07

该回顾性研究纳入2015年至2019年131,268例接受下肢静脉评估的患者,按年龄≥65岁(A组)与<65岁(B组)分组,比较不同治疗方式的长期结果。结果显示,A组在消融联合剥脱±UGFS后rVCSS需6个月达到B组1个月的改善程度,但CIVIQ-20均在1个月改善;TA与VA疗效相当。

要点

  • Medicare资格患者消融术后结局与非Medicare资格患者相似。
  • TA或VA联合剥脱±UGFS后,老年组rVCSS改善滞后至6个月。
  • CIVIQ-20评分两组均在1个月改善,与治疗方式无关。

核心结论

  • Medicare资格患者消融术后结局与非Medicare资格患者相似。
  • TA或VA联合剥脱±UGFS后,A组需6个月达到B组1个月的rVCSS改善程度。
  • CIVIQ-20评分两组均在1个月改善,与治疗方式无关。
  • rVCSS差异似由非裔美国人和白人患者驱动,西班牙裔和亚裔患者结果相当。
  • TA与VA治疗结果相当。

研究设计与样本

  • 回顾性研究,2015年1月至2019年12月,纳入131,268例接受下肢静脉评估的患者。
  • 按年龄分组:A组≥65岁(40,020例),B组<65岁(91,248例)。
  • 分析的治疗包括轴向热消融(TA)、轴向Varithena消融(VA)、TA+剥脱、VA+剥脱、TA或VA+剥脱+超声引导泡沫硬化疗法(UGFS)。
  • 结局评估采用修订版静脉临床严重程度评分(rVCSS)和慢性静脉功能不全生活质量20项问卷(CIVIQ-20),在初诊及治疗完成后1、6、12个月评估。

主要发现

  • A组平均年龄74.4±6.6岁,B组49.9±10.6岁。
  • A组中15,697例(25,234条肢体)接受TA,1910例(3222条肢体)接受VA。
  • B组中35,220例(53,717条肢体)接受TA,2178例(3672条肢体)接受VA。
  • TA亚组所有rVCSS在治疗后各评估点均显著改善(P≤.001)。
  • TA或VA联合剥脱±UGFS亚组中,A组需6个月达到B组1个月的rVCSS改善程度。

临床怎么用

  • 对于Medicare资格患者,消融术后结局与非Medicare资格患者相似,可预期相似疗效。
  • 老年患者接受TA或VA联合剥脱±UGFS后,rVCSS改善可能滞后至6个月,应适当延长随访评估。
  • CIVIQ-20评分在1个月即可改善,可用于早期生活质量评估。
  • TA与VA疗效相当,治疗选择可个体化。

局限性

  • 回顾性研究设计。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We previously reported that chronic venous insufficiency treatment of Medicare-eligible patients achieved outcomes similar to those for non-Medicare-eligible patients. The goal of the present investigation was to assess the long-term treatment outcomes and the effect of race in a larger patient cohort. METHODS: From January 2015 to December 2019, we retrospectively reviewed the data from 131,268 patients who had presented for a lower extremity venous evaluation. We divided the patients into two groups by age: group A was aged ≥65 years and group B, <65 years. The treatments analyzed in each group were axial thermal ablation (TA), axial Varithena ablation (VA), TA plus phlebectomy, VA plus phlebectomy, and TA or VA with phlebectomy and ultrasound-guided foam sclerotherapy (UGFS). The treatment outcomes were assessed using the revised venous clinical severity score (rVCSS) and Chronic Venous Insufficiency Quality of Life 20-item questionnaire (CIVIQ-20) scores at the initial consultation and 1, 6, and 12 months after completion of the treatment plan. RESULTS: Of the 131,268 patients, 40,020 were in group A and 91,248 in group B, with an average age of 74.4 ± 6.6 and 49.9 ± 10.6 years, respectively. Of the 40,020 patients in group A, 15,697 (n = 25,234 limbs) had undergone TA and 1910 (n = 3222 limbs) had undergone VA. Of the 91,248 patients in group B, 35,220 (n = 53,717 limbs) had undergone TA and 2178 (n = 3672 limbs) had undergone VA. For the TA subgroups, all rVCSSs had significantly improved after treatment at each evaluation point (P ≤ .001). For the TA and VA plus phlebectomy with or without UGFS subgroup, the older patients (group A) required 6 months to develop the same degree of improvement as the younger patients (group B) at 1 month. When subdivided by race, all initial and 6-month rVCSSs and CIVIQ-20 scores within a race had improved and were better in group B, except for Asian and Hispanic patients (P ≤ .001). After TA or VA plus phlebectomy, with or without UGFS, the CIVIQ-20 outcomes had improved by 1 month in both groups, although the rVCSS lagged by 6 months in group A. No differences in the rVCSSs or CIVIQ-20 scores were observed between the groups treated with TA or VA. CONCLUSIONS: Medicare-eligible beneficiaries demonstrated improved outcomes similar to those of non-Medicare-eligible beneficiaries after ablation. When TA or VA plus phlebectomy with or without UGFS were examined, group A required 6 months to demonstrate rVCSSs equivalent to those of group B at 1 month. The CIVIQ-20 scores had improved by 1 month in both groups, regardless of the treatment modality. The difference in rVCSSs appeared to be driven by African American and white patients because Hispanic and Asian patients demonstrated equivalent results regardless of age. Patients treated with TA or VA demonstrated equivalent results.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Pappas PJ, Lakhanpal S, Nguyen KQ, et al. Extended Center for Vein Restoration study assessing comparative outcomes for the treatment of chronic venous insufficiency in Medicare- and non-Medicare-eligible patients. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33965612. doi:10.1016/j.jvsv.2021.04.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。